Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLYC-101 for wound healing after CO2 laser skin resurfacing
NCT00792688Phase 2Completed
- Sponsor
- TR Therapeutics
- Start
- Oct 2008
- Primary completion
- Jan 2010
- Modality
- Polysaccharide, Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TR-987 in wound (3 arms), sponsored by TR Therapeutics. Primary endpoint: Time to Complete Wound Closure (Epithelialization) at 1 month. Started Oct 2008; status: completed.
02
Drugs
TR-987
03
Conditions
wound
Beyond the preview
Go deeper on NCT00792688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00792688.